Key Takeaways
- The Centers for Medicare & Medicaid Services confirmed a 2.48% net average payment increase for 2027 Medicare Advantage plans — representing more than $13 billion in additional sector funding
- Shares of CVS Health surged by as much as 5.20% during Tuesday’s session, with its Aetna insurance division positioned to benefit significantly
- The 2024 risk-adjustment model will remain in effect for 2027, accompanied by stricter regulations on diagnoses from unlinked chart reviews
- Cantor Fitzgerald maintained its Overweight recommendation with a $95 price objective, highlighting Medicare Advantage margin improvement as a critical catalyst
- The company’s Q1 2026 earnings release is scheduled for May 6, with analysts projecting earnings per share of $2.23 on revenues of $94.86 billion
CVS Health experienced a significant rally on Tuesday following a Medicare Advantage regulatory announcement that lifted managed-care stocks across the board.
The Centers for Medicare & Medicaid Services released its final 2027 payment framework for Medicare Advantage and Part D programs, establishing a net average reimbursement increase of 2.48% — which equates to approximately $13 billion in incremental funding industrywide for the 2027 calendar year.
This development carries substantial weight for CVS Health. The company maintains significant Medicare Advantage operations through Aetna, complementing its pharmacy benefit management and retail drugstore businesses.
Investors responded favorably to the announcement. Shares jumped as high as 5.20% during Tuesday’s early trading session.
Regulatory Details Include Tighter Risk-Adjustment Standards
The policy update contained nuanced provisions beyond the headline rate increase. CMS announced it will maintain the 2024 risk-adjustment framework through 2027, while implementing restrictions that exclude diagnoses derived from unlinked chart reviews in the majority of risk-score computations.
These enhanced standards could present challenges for insurers heavily reliant on coding-focused reimbursement tactics. However, market participants appeared to prioritize the overall funding boost over the risk-adjustment modifications when evaluating CVS’s diversified business model.
The company has also seen progress in its Stars ratings performance. CVS experienced a dramatic decline in bonus-eligible Stars coverage from 85% in 2022 to just 21% in 2023 — a downturn that significantly pressured Medicare Advantage profitability during that timeframe.
Cantor Fitzgerald, which reaffirmed its Overweight stance with a $95 price objective on Monday, noted that while the Medicare Advantage segment hasn’t yet achieved 3% margin targets, the firm estimates 2026 individual Medicare Advantage operations are marginally profitable.
Shares were changing hands at $73.28 prior to Tuesday’s advance, a valuation level that Cantor and other research firms consider discounted relative to intrinsic worth.
Wall Street Maintains Positive Outlook Ahead of Early May Earnings
The analyst consensus tilts decidedly bullish on CVS Health. The equity holds a consensus Buy recommendation with an average price objective of $92.79.
Recent research actions include Bernstein’s March upgrade to Outperform with a $94 target, Piper Sandler’s Overweight rating with a reduced $99 objective, and Argus Research’s continued Buy rating at $90.
Leerink Partners maintains an Outperform designation with a $98 target, a perspective influenced partly by the recent FTC consent agreement related to Caremark and Zinc, which analysts interpreted as eliminating regulatory overhang.
On the strategic front, CVS recently disclosed an asset acquisition arrangement with GenieRx Holdings, designating GenieRx as the stalking horse bidder in the bankruptcy sale proceedings for Omnicare.
The healthcare giant also named John E. Gallina, previously chief financial officer at Elevance Health, to its board of directors and audit committee.
Looking ahead: CVS is set to release first-quarter 2026 results on May 6. Consensus estimates call for earnings per share of $2.23 and revenue of $94.86 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
